New cocktail of drugs targets Hard-to-Treat bile duct cancer
NCT ID NCT07159217
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a combination of three drugs—disitamab vedotin, lenvatinib, and a PD-1 inhibitor—for people with HER2-positive advanced biliary tract cancer that cannot be removed by surgery. The study will enroll 65 participants to see how well the treatment shrinks tumors and controls the disease. Researchers will also monitor side effects closely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- disitamab vedotin, lenvatinib, and a PD-1 inhibitor (pembrolizumab, toripalimab, or camrelizumab)
- What this could lead to
- If successful, this could point toward a new treatment option for people with HER2-positive advanced biliary tract cancer, potentially shrinking tumors and extending life.
- What could go wrong
- This is an early phase 2 trial with only 65 participants and no comparison group, so results may not be definitive. The combination of three drugs may cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese Academy of Medical Sciences, Peking Union Medical College Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can an immune booster after lung cancer surgery keep the disease at bay?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a Triple-Drug combo outsmart a rare and aggressive cancer?